Brief: New Data Demonstrate Clinical Utility Of Veracyte’S Decipher Prostate Genomic Classifier In Tailoring Treatment For Prostate Cancer Patients Experiencing Progression After Surgery
26/10/2021 14:27
Oct 26 (Reuters) - Veracyte Inc VCYT.O :
* NEW DATA DEMONSTRATE CLINICAL UTILITY OF VERACYTE’S
DECIPHER
PROSTATE GENOMIC CLASSIFIER IN TAILORING TREATMENT FOR PROSTATE
CANCER PATIENTS EXPERIENCING PROGRESSION AFTER SURGERY
Source text for Eikon: ID:nBw7k7dda
Further company coverage: VCYT.O
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina